Evidence map›Paper›PMID 28243988›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence.

P Jimenez-Fonseca, A Carmona-Bayonas, C Calderon, J Fontcuberta Boj, C Font, R Lecumberri, M Monreal, A J Muñoz Martín, R Otero, A Rubio and 4 more

Abstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Key points to optimizing management and research on cancer-associated thrombosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

P Jimenez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. palucaji@hotmail.com.ORCID http://orcid.org/0000-0003-4592-3813
A Carmona-BayonasHematology and Medical Oncology Department, UMU, IMIB, Hospital Universitario Morales Meseguer, Murcia, Spain.
C CalderonClinical Psychology and Psychobiology Department, Faculty of Psychology, University of Barcelona, Barcelona, Spain.
J Fontcuberta BojUnitat d'Hemostàsia i Trombosi, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
C FontMedical Oncology Department, IDIBAPS/Translational Genomics and Targeted Therapeutics in Solid Tumors, Hospital Universitari Clínic, Barcelona, Spain.
R LecumberriHemaotology Department, Clínica Universidad de Navarra, Pamplona, Spain.
M MonrealInternal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
A J Muñoz MartínMedical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
R OteroMedical-Surgical Unit for Respiratory Disease, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Sevilla, Spain.
A RubioPharmacy Department, Hospital Virgen de la Salud, Toledo, Spain.
P Ruiz-ArtachoEmergency Department, Hospital Universitario Clínico San Carlos, IdISSC, Madrid, Spain.
C Suarez FernándezInternal Medicine Department, Hospital Universitario La Princesa, Madrid, Spain.
E ColomeScientific Affairs, LEO Pharma, Barcelona, S.A, Spain.
P Pérez SeguraMedical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDecision-making in cancer-related venous thromboembolism (VTE) is often founded on scant lines of evidence and weak recommendations. The aim of this work is to evaluate the percentage of agreement surrounding a series of statements about complex, clinically relevant, and highly uncertain aspects to formulate explicit action guidelines. MATERIALS AND

methodsOpinions were based on a structured questionnaire with appropriate scores and were agreed upon using a Delphi method. Questions were selected based on a list of recommendations with low evidence from the Spanish Society of Oncology Clinical Guideline for Thrombosis. The questionnaire was completed in two iterations by a multidisciplinary panel of experts in thrombosis.

resultsOf the 123 statements analyzed, the panel concurred on 22 (17%) and another 81 (65%) were agreed on by qualified majority, including important aspects of long-term and prolonged anticoagulation, major bleeding and rethrombosis management, treatment in special situations, catheter-related thrombosis and thromboprophylaxis. Among them, the panelists agreed the incidental events should be equated to symptomatic ones, long-term and extended use of full-dose low-molecular weight heparin, and concluded that the Khorana score is not sensitive enough to uphold an effective thromboprophylaxis strategy.

conclusionThough the level of consensus varied depending on the scenario presented, overall, the iterative process achieved broad agreement as to the general treatment principles of cancer-associated VTE. Clinical validation of these statements in genuine practice conditions would be useful.

Indexed as

AnticoagulantsEvidence-Based MedicineHumansMedical OncologyNeoplasmsPractice Guidelines as TopicPrognosisRisk AssessmentThrombosisAnticoagulantsCancer-associated thrombosisDelphi consensusLow-molecular weight heparinProphylaxisRecommendationsTreatmentVenous thromboembolism

Identifiers

PMID28243988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.